Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 <scp>ALLG MM23</scp> ( <scp>SeaLAND</scp> ) trial
- DOI
- 10.1111/bjh.70851
- Published
- 2026-09-22
- Container
- British Journal of Haematology
- Publisher
- Wiley
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1111/bjh.70851,
title = {Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3
<scp>ALLG MM23</scp>
(
<scp>SeaLAND</scp>
) trial},
author = {Matthew J. Rees and Masa Lasica and Anna Kalff and Michael Low and Rosemary Harrup and Hock Choong Lai and M. Hasib Sidiqi and Nicole Wong Doo and David Routledge and Jay Hocking and Philip Campbell and Jessica Heenan and Noemi Horvath and Nicole Chien and William E. P. Renwick and Georgia McCaughan and Richard Eek and Douglas S. Lenton and Tricia Wright and Sher Gul Gazdar and Deepmala Mazumdar and Belinda Butcher and Peter Mollee and Hang Quach and Unknown},
year = {2026},
journal = {British Journal of Haematology},
doi = {10.1111/bjh.70851},
url = {https://doi.org/10.1111/bjh.70851}
}RIS
TY - JOUR
TI - Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3
<scp>ALLG MM23</scp>
(
<scp>SeaLAND</scp>
) trial
AU - Matthew J. Rees
AU - Masa Lasica
AU - Anna Kalff
AU - Michael Low
AU - Rosemary Harrup
AU - Hock Choong Lai
AU - M. Hasib Sidiqi
AU - Nicole Wong Doo
AU - David Routledge
AU - Jay Hocking
AU - Philip Campbell
AU - Jessica Heenan
AU - Noemi Horvath
AU - Nicole Chien
AU - William E. P. Renwick
AU - Georgia McCaughan
AU - Richard Eek
AU - Douglas S. Lenton
AU - Tricia Wright
AU - Sher Gul Gazdar
AU - Deepmala Mazumdar
AU - Belinda Butcher
AU - Peter Mollee
AU - Hang Quach
AU - Unknown
PY - 2026
JO - British Journal of Haematology
DO - 10.1111/bjh.70851
UR - https://doi.org/10.1111/bjh.70851
ER - APA
Rees, M. J., Lasica, M., Kalff, A., Low, M., Harrup, R., Lai, H. C., Sidiqi, M. H., Doo, N. W., Routledge, D., Hocking, J., Campbell, P., Heenan, J., Horvath, N., Chien, N., Renwick, W. E. P., McCaughan, G., Eek, R., Lenton, D. S., Wright, T., Gazdar, S. G., Mazumdar, D., Butcher, B., Mollee, P., Quach, H., & Unknown (2026). Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 <scp>ALLG MM23</scp> ( <scp>SeaLAND</scp> ) trial. British Journal of Haematology. https://doi.org/10.1111/bjh.70851
Source records
- crossref · retrieved 2026-09-25T02:50:27.403Z